Thermo Fisher Scientific Inc.

NYSE:TMO

Medical - Diagnostics & Research

Healthcare
$692.74 +0.96%

+$4.45 today

Market cap
$256.67B
Beta
0.87
P/E (TTM)
25.3
EPS (TTM)
$18.44
Dividend yield
0.39%
52W Low $390.50High $643.99

Volume 1.99M

Average 2.23M

TMO Depreciation & Amortization

Non-cash asset write-downs added back to net income because no cash left the business.

Thermo Fisher Scientific Inc.NYSE: TMO

Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026

Depreciation & amortization growth accelerates

Q3 FY2026 depreciation & amortization of $825M rose 24.8% year over year, ahead of the +11.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 1.0% from the prior quarter. Over 3 fiscal years it compounded at -6.3% a year.

Context

  • Depreciation & amortization amounted to 6.2% of revenue in FY2025, down 1.0 pp from a year earlier.
  • Depreciation & amortization increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +24.8% holds above the trailing-twelve-month pace of +11.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
$825M+1.0% QoQ
Last fiscal yearDec 2025
$2.78B-10.6% YoY
LTMSep 2026
$3.11B+11.2% YoY
Depreciation & Amortization past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.8%——
1 year-10.6%——
3-year CAGR-6.3%——
5-year CAGR——
10-year CAGR——

Depreciation & Amortization history

USD · from the cash flow

Latest · FY2025
2.78B USD
Year-over-year change
-10.6%
4-year CAGR
+1.8%

Depreciation & Amortization vs competitors

How TMO compares with its peers on the latest reported figures

  • TMO's LTM Sep 2026 depreciation & amortization of $3.11B is the largest of the 10 companies compared; the peer median is $230.1M.
  • Its year-over-year change of +11.2% is the 2nd highest of 10, against a peer median of -0.2%.
  • Depreciation & amortization amounts to 6.6% of revenue for TMO, versus a peer median of 7.5%.
TMO Competitors Peer median
Depreciation & Amortization for TMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TMOThermo Fisher Scientific Inc.LTM Sep 2026$3.11B +11.2%-6.3%6.6%
DHRDanaher CorporationLTM Sep 2026$1.91B -21.1%+4.7%7.5%
WATWaters CorporationLTM Jul 2026$613.22M +211.1%+16.5%13.2%
RVTYRevvity, Inc.LTM Jul 2026$412.24M -0.2%-1.7%14.2%
AAgilent Technologies, Inc.LTM Jul 2026$271M -5.2%-3.1%3.7%
BRKRBruker CorporationLTM Jun 2026$230.1M +9.4%+35.4%6.6%
QGENQiagen N.V.LTM Jun 2026$202.13M +7.0%-2.4%9.6%
MTDMettler-Toledo International Inc.LTM Jun 2026$131M +7.3%+3.6%3.2%
BIOBio-Rad Laboratories, Inc.LTM Jun 2026$127.6M -23.5%+6.4%4.9%
TECHBio-Techne CorporationLTM Sep 2026$96.75M -8.8%-3.2%7.9%
Peer median (excluding TMO) $230.1M-0.2%+3.6%7.5%

Competitors are the stored peer set for TMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income7.73B6.96B6B6.34B6.72B
Depreciation & Amortization2.59B3.38B3.41B3.11B2.78B
Deferred Income Tax(406M)(995M)(1.3B)(1.21B)(639M)
Stock-Based Compensation230M307M278M301M310M
Change in Working Capital(1.56B)(1.05B)(537M)(334M)(1.77B)
Accounts Receivables(204M)(430M)209M(171M)(426M)
Inventory(1.07B)(825M)598M(27M)(74M)
Accounts Payables479M648M(500M)212M421M
Other Working Capital(768M)(442M)(844M)(348M)(1.69B)
Other Non-Cash Items957M550M564M463M412M
Operating Cash Flow9.54B9.15B8.41B8.67B7.82B
Capital Expenditures(2.52B)(2.24B)(1.48B)(1.4B)(1.53B)
Acquisitions (Net)(19.4B)(39M)(3.66B)(3.13B)(4.04B)
Purchases of Investments(8M)(15M)0(3.4B)(383M)
Sales of Investments8M15M70M1.77B1.57B
Other Investing Activities(14M)123M(73M)317M333M
Investing Cash Flow(21.93B)(2.16B)(5.14B)(5.84B)(4.05B)
Debt Repayment8.91B654M(155M)(2.4B)5.35B
Common Stock Issued00000
Common Stock Repurchased(2B)(3B)(3B)(4B)(3B)
Dividends Paid(395M)(455M)(523M)(583M)(636M)
Other Financing Activities65M(9M)56M194M90M
Financing Cash Flow6.58B(2.81B)(3.62B)(6.79B)1.8B
Effect of Forex Changes(37M)(139M)(82M)(91M)267M
Net Change in Cash(5.85B)4.05B(440M)(4.06B)5.84B
Free Cash Flow7.02B6.91B6.93B7.27B6.29B

Thermo Fisher Scientific Inc.

NYSE:TMO

Intrinsic Alpha fair value

Locked

Current Price

$692.74

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.